GlassScriptPhysician profile
Indrajit Choudhuri
NPI 1467621110
$44,679.84
in general payments reported to CMS, 2019-2025
26 companies · $736 in 2025
The $736 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $22K · 2021: $943 · 2022: $653 · 2023: $339 · 2024: $494 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.64 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $21,241.74 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,330.82 | 2019-2023 | Lifevest |
| Biotronik INC. | $5,840.15 | 2019-2022 | |
| Cardiofocus, INC. | $4,911.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,212.65 | 2019-2024 | Xarelto |
| Atricure, INC. | $689.66 | 2019-2023 | |
| Biosense Webster, INC. | $459.38 | 2019-2025 | Carto 3 |
| Abbott Laboratories | $423.50 | 2020-2025 | Cardiomems |
| Boston Scientific Corporation | $320.12 | 2023-2025 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $266.25 | 2025 | Camzyos, Eliquis |
| Amgen INC. | $179.78 | 2020-2022 | |
| Heartflow, INC. | $173.78 | 2024-2025 | |
| Medtronic Vascular, INC. | $105.87 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $100.70 | 2024-2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $92.74 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.98 | 2019-2023 | Jardiance |
| Pfizer INC. | $57.71 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $45.93 | 2024 | |
| Merck Sharp & Dohme LLC | $24.05 | 2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $21.33 | 2023 | Assure Wcd |
| Recor Medical INC | $19.51 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.55 | 2025 | Farxiga |
| Corcept Therapeutics | $16.41 | 2024 | Korlym |
| Medtronic, INC. | $13.29 | 2022 | |
| Bardy Diagnostics, INC. | $4.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indrajit Choudhuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.